期刊
EXPERT REVIEW OF VACCINES
卷 8, 期 10, 页码 1399-1413出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.09.95
关键词
antibody; anticancer vaccine; carbohydrate antigen; epitope; glycoconjugate; glycopeptide; mucin; oligosaccharide
类别
资金
- NIH [CA28824]
- NATIONAL CANCER INSTITUTE [R01CA028824, R37CA028824] Funding Source: NIH RePORTER
Malignantly transformed cells can express aberrant cell surface glycosylation patterns, which serve to distinguish them from normal cells. This phenotype provides an opportunity for the development of carbohydrate-based vaccines for cancer immunotherapy. Synthetic carbohydrate-based vaccines, properly introduced through vaccination of a subject with a suitable construct, should be recognized by the immune system. Antibodies induced against these carbohydrate antigens could then participate in the eradication of carbohydrate-displaying tumor cells. Advances in carbohydrate synthetic capabilities have allowed us to efficiently prepare a range of complex, synthetic anticancer vaccine candidates. We describe herein the progression of our longstanding carbohydrate-based anticancer vaccine program, which is now at the threshold of clinical evaluation in several contexts. Our carbohydrate-based anticancer vaccine program has evolved through a number of stages: monomeric vaccines, monomeric clustered vaccines, unimolecular multi-antigenic vaccines and dual-acting vaccines. This account will focus on our recently developed unimolecular multi-antigenic constructs and potential dual-acting constructs, which contain clusters of both carbohydrate and peptide epitopes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据